Yuekang Pharmaceutical's broad-spectrum anti-new crown peptide drug was approved for clinical trial

Yuekang Pharmaceutical's YOUCARE WeChat public account said: Recently, Yuekang Pharmaceutical's broad-spectrum coronavirus membrane fusion inhibitor peptide drug (YKYYO17 nebulized inhalant) has been approved by the National Medical Products Administration for clinical trials. YKYY017 aerosolized inhaler is a chemical drug class 1 innovative drug with a clear mechanism of action, precise efficacy and completely independent intellectual property rights developed by the company, and the indication of this application is the treatment of new coronavirus infection.

The clinical approval of this nebulized inhaler is of great significance, and the peptide drug inhalation preparation is an innovative high-end preparation, which realizes the efficient utilization of peptide drugs through inhalation lung delivery, so that peptide drugs exert systemic efficacy and has broad application prospects.

YKYY017 nebulized inhaler is the latest generation of broad-spectrum, highly effective coronavirus membrane fusion inhibitor jointly developed by Yuekang Pharmaceutical and the Institute of Pathogenic Biology of the Chinese Academy of Medical Sciences, which can exert antiviral effects by inhibiting the two membrane fusion pathways of cell surface and endocytosome, and Yuekang Pharmaceutical has the exclusive rights of YKYY017 worldwide.

At present, the epidemic situation of the new crown epidemic at home and abroad is still grim, and the demand for effective epidemic prevention and control products is urgent. The YKYY017 aerosol inhaler for therapeutic use is a product with independent intellectual property rights in China that can be used to treat new coronavirus infection, which will further help protect people's lives and health.